(Q33941574)

30 July 2017

1 reference

title

Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer (English)

1 reference

30 July 2017

1 reference

ChEBI release 2020-05-28

2

1 reference

30 July 2017

Sarah M Scott

1

1 reference

PubMed ID

21699443

30 July 2017

Steven E Come

series ordinal

3

1 reference

PubMed ID

21699443

30 July 2017

language of work or name

English

0 references

publication date

24 June 2011

1 reference

Expert Opinion on Drug Safety

30 July 2017

1 reference

30 July 2017

10

1 reference

30 July 2017

5

1 reference

30 July 2017

819-826

1 reference

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer

30 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Proteasome-dependent degradation of the human estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Nuclear receptor coregulators: cellular and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Fulvestrant (Faslodex) -- how to make a good drug better

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Model systems: mechanisms involved in the loss of sensitivity to letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Early discontinuation of tamoxifen: a lesson for oncologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.595560

10.1517/14740338.2011.595560

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

21699443